Jim Clemmer: 'Auryon continued to deliver outstanding results, growing 25%... We received CE mark approval for Auryon, which is a significant milestone.'
— Jim Clemmer
03Detailed Report
ANGO
AngioDynamics Inc
Period
Q1 2025
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 28, 2026
Swipe to view all report sections
Executive Summary
AngioDynamics Inc (NASDAQ: ANGO) kickstarted fiscal Q1 2025 with a revenue of $67.5 million, reflecting a modest growth of 1.1% year-over-year. The increase was largely driven by strong performance in the MedTech segment, which reported 9% growth spurred by the success of Auryon and AlphaVac products, both of which saw substantial revenue increases. However, the company reported an adjusted EBITDA loss of $200K and a net loss of $12.8 million, signaling ongoing challenges in attaining profitability despite sales growth. Management emphasized continued focus on enhancing operational efficiency and expanding product offerings as pathways toward improving margins and achieving a breakeven cash flow status in the fiscal 2026. Overall, while there are promising growth drivers within the product portfolio, the company still faces significant hurdles in managing costs and achieving sustained profitability.
Key Performance Indicators
Revenue
Decreasing
67.49M
QoQ: -4.92% | YoY: -14.22%
Gross Profit
Decreasing
36.72M
54.41% margin
QoQ: 2.18% | YoY: -8.33%
Operating Income
Decreasing
-13.10M
QoQ: -125.63% | YoY: -137.39%
Net Income
Decreasing
-12.80M
QoQ: 4.84% | YoY: -127.89%
EPS
Decreasing
-0.31
QoQ: 6.06% | YoY: -126.96%
Revenue Trend
Margin Analysis
Financial Highlights
Key Financial Metrics for Q1 2025
- Revenue: $67.5 million, a year-over-year increase of 1.1% driven primarily by MedTech segment growth.
- Gross Profit: $36.7 million, translating to a gross margin of 54.4%, down from 54.8% a year prior.
- Net Income: Net loss of $12.8 million or -$0.31 per diluted share, compared to -$6.4 million or -$0.16 per diluted share in the previous year.
- Operating Cash Flow: Utilized $18.3 million. Despite losses, cash at quarter-end stood at $55 million, down from $76 million at the start of the quarter.
- Debt Profile: Zero debt, demonstrating a strengthened balance sheet position relative to previous debt burdens with $50 million at the start of fiscal 2024.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
67.49M
-14.22%
-4.92%
Gross Profit
36.72M
-8.33%
2.18%
Operating Income
-13.10M
-137.39%
-125.63%
Net Income
-12.80M
-127.89%
4.84%
EPS
-0.31
-126.96%
6.06%
Key Financial Ratios
Gross Profit Margin
Good
54.40%
Gross profit margin is healthy and competitive within industry standards
Operating Profit Margin
Weak
-0.19%
Operating margin is below industry norms, profitability concerns
Net Profit Margin
Weak
-0.19%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.04%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.07%
Return on equity suggests inefficient capital allocation
Current Ratio
Healthy
2.25
Current ratio shows adequate liquidity to meet short-term obligations
Debt to Equity
Conservative
0.02
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-5.92x
Negative earnings make P/E ratio not meaningful
Price to Book
Fair Value
1.54x
Price-to-book ratio reasonable for profitable companies
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.